OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/BRAF
Lung Cancer — Non-Small Cell (NSCLC)BRAF Clinical Trials
BRAF V600E mutations occur in 2–3% of NSCLC and are targetable with the FDA-approved dabrafenib plus trametinib combination. Non-V600 BRAF mutations (Class II and III) are less common and respond differently to BRAF/MEK inhibition. Clinical trials explore novel BRAF inhibitors, next-generation combinations, and strategies for non-V600E BRAF-altered NSCLC.
Top recruiting BRAF Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
ImmunityBio, Inc.
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK